Hangzhou-based protein drug developer JHM Biopharma has reportedly secured close to RMB100 million (USD14.9 million) in a Series A+ financing round. The funding was led by 3E Bioventures and Guangdian Capital. Proceeds from the round will be allocated towards the development and expansion of JHM Biopharma’s product pipeline, as well as the construction of a GMP-certified manufacturing plant.
Platform and Pipeline Development
Founded in 2020, JHM Biopharma has established itself as a leader in the development of innovative recombinant protein drugs. The company’s platform features a high-efficiency expression system for recombinant proteins, unique micro-denaturation separation and purification technology, an in vitro protein folding and self-assembly system, and long-term sustained release capabilities. These technologies collectively support the development of next-generation protein therapies.
Focus on Metabolic Diseases and Medical Aesthetics
JHM Biopharma’s pipeline is primarily focused on addressing unmet needs in metabolic diseases and medical aesthetics. By leveraging its proprietary platform, the company aims to develop novel protein-based treatments that offer improved efficacy, safety, and convenience compared to existing options. The Series A+ funding will accelerate the advancement of these pipeline candidates, bringing them closer to clinical validation and commercialization.
Implications for Future Growth
The successful completion of the Series A+ financing round underscores JHM Biopharma’s potential to drive innovation in the protein drug space. With strong financial backing and a robust development platform, the company is well-positioned to expand its product offerings and address significant market opportunities in both therapeutic and aesthetic areas. The construction of a GMP-certified manufacturing plant will further enhance JHM Biopharma’s capabilities, supporting its long-term growth and competitiveness.-Fineline Info & Tech
